PDF(Pubmed)
Abstract：
There are limited treatment options for patients with advanced vulvar cancer. However, several immune checkpoint inhibitors (ICIs) are FDA-approved or NCCN-Compendia-listed for qualified patients with advanced disease. In this case report, we present a patient with metastatic vulvar squamous cell carcinoma who was treated with pembrolizumab in the setting of disease progression following prior treatment with radiation and chemotherapy. Best response to immunotherapy was an unconfirmed partial response. We summarize the current role of ICIs in treating advanced vulvar cancer, which is largely extrapolated from the squamous cell skin cancer and cervical cancer guidelines. Additionally, we emphasize the need for more inclusive clinical trials and a better understanding of vulvar cancer molecular biology, as well as the identification of biomarkers to predict response to targeted therapy in patients with advanced vulvar cancer.
摘要：
晚期外阴癌患者的治疗选择有限。然而,几种免疫检查点抑制剂(ICIs)已获得FDA批准或NCCN-Compendia上市,适用于符合资格的晚期疾病患者.在这个案例报告中,我们介绍了1例转移性外阴鳞状细胞癌患者,该患者在接受放疗和化疗治疗后,在疾病进展的情况下接受了派博利珠单抗治疗.对免疫疗法的最佳反应是未经证实的部分反应。我们总结了ICIs在治疗晚期外阴癌中的当前作用，这在很大程度上是从鳞状细胞皮肤癌和宫颈癌指南中推断出来的。此外,我们强调需要更具包容性的临床试验和更好地了解外阴癌分子生物学，以及识别生物标志物以预测晚期外阴癌患者对靶向治疗的反应。
